Prognostic significance of anatomical resection and des-γ-carboxy prothrombin in patients with hepatocellular carcinoma

被引:195
|
作者
Imamurai, H
Marsuyama, Y
Miyagawa, Y
Ishida, K
Shimada, R
Miyagawa, S
Makuuchi, M
Kawasaki, S
机构
[1] Univ Tokyo, Grad Sch Med, Dept Surg, Div Hepatobiliary Pancreat Surg,Bunkyo Ku, Tokyo 1138655, Japan
[2] Univ Tokyo, Sch Hlth Sci & Nursing, Dept Biostat, Tokyo 1138655, Japan
[3] Shinshu Univ, Sch Med, Dept Surg 1, Nagano, Japan
关键词
D O I
10.1046/j.1365-2168.1999.01185.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Portal venous tumour extension and intrahepatic metastasis result in a poor prognosis following hepatectomy for hepatocellular carcinoma (HCC). Anatomical resection is, in theory, preferable for eradicating these types of invasion. Des-gamma-carboxy prothrombin (DCP) has been reported to be associated with adverse pathological variables. This study investigated the significance of anatomical resection and DCP as predictive factors for postoperative recurrence of HCC. Methods: A retrospective cohort study was carried out in 138 consecutive patients who underwent hepatectomy for RCC smaller than 5 cm using the Cox proportional hazards model. Results: Eight factors were univariately related to poor prognosis (in decreasing order of hazard ratio): intrahepatic metastasis, multiple tumours, a-fetoprotein 32ng/ml or more; DCP greater than 0.1 arbitrary units (AU), tumour-exposed surgical margin, vascular invasion, non-anatomical resection and tumour 2.5 cm or more. Three variables (DCP, vascular invasion and tumour-exposed surgical margin) mere excluded by a stepwise procedure in multivariate analysis. Although DCP was not an independent prognostic factor, a model replacing intrahepatic metastasis with DCP showed similar predictive accuracy in a receiver-operating characteristic curve. Conclusion: Anatomical resection appeared to have a beneficial effect on recurrence-free survival after hepatectomy for RCC. DCP measurement was effective in predicting HCC recurrence and had the advantage that it can be assessed before operation.
引用
收藏
页码:1032 / 1038
页数:7
相关论文
共 50 条
  • [21] HYPOXIA-INDUCED DES-γ-CARBOXY PROTHROMBIN PRODUCTION IN HEPATOCELLULAR CARCINOMA
    Murata, Kazumoto
    HEPATOLOGY, 2009, 50 (04) : 615A - 616A
  • [22] The role of des-γ-carboxy prothrombin levels in hepatocellular carcinoma and liver tissues
    Shimada, M
    Yamashita, Y
    Hamatsu, T
    Hasegawa, H
    Utsunomiya, T
    Aishima, S
    Sugimachi, K
    CANCER LETTERS, 2000, 159 (01) : 87 - 94
  • [23] Phenotype-dependent production of des-γ-carboxy prothrombin in hepatocellular carcinoma
    Hideto Suzuki
    Kazumoto Murata
    Takaya Gotoh
    Masao Kusano
    Hiroshi Okano
    Takashi Oyamada
    Yoshikazu Yasuda
    Masatoshi Imamura
    Masatoshi Kudo
    Masashi Mizokami
    Atsushi Sakamoto
    Journal of Gastroenterology, 2011, 46 : 1219 - 1229
  • [24] Hypoxia-induced des-γ-carboxy prothrombin production in hepatocellular carcinoma
    Murata, Kazumoto
    Suzuki, Hideto
    Okano, Hiroshi
    Oyamada, Takashi
    Yasuda, Yoshikazu
    Sakamoto, Atsushi
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2010, 36 (01) : 161 - 170
  • [25] Clinicopathologic features of patients with hepatocellular carcinoma seropositive for α-fetoprotein-L3 and seronegative for des-γ-carboxy prothrombin in comparison with those seropositive for des-γ-carboxy prothrombin alone
    Okuda, H
    Nakanishi, T
    Takatsu, K
    Saito, A
    Hayashi, N
    Yamamoto, M
    Takasaki, K
    Nakano, M
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 (07) : 772 - 778
  • [26] A new prognostic scoring system involving des-γ-carboxy prothrombin as a useful marker for predicting prognosis in patients with hepatocellular carcinoma
    Kawakita, T
    Shiraki, K
    Yamanaka, Y
    Yamaguchi, Y
    Saitou, Y
    Enokimura, N
    Yamamoto, N
    Okano, H
    Sugimoto, K
    Murata, K
    Yamakado, K
    Takeda, K
    Nakano, T
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 23 (04) : 1115 - 1120
  • [27] Des-γ-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma.
    Fujikawa, T
    Suzuki, M
    Shiraha, H
    Takaoka, N
    Ueda, N
    Nakanishi, Y
    Koike, K
    Takaki, A
    Shiratori, Y
    HEPATOLOGY, 2004, 40 (04) : 602A - 603A
  • [28] Des-γ-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma
    Tang, W
    Miki, K
    Kokudo, N
    Sugawara, Y
    Imamura, H
    Minagawa, M
    Yuan, LW
    Ohnishi, S
    Makuuchi, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 22 (05) : 969 - 975
  • [29] Clinical utility of des-γ-carboxy prothrombin (DCP) as a biomarker for hepatocellular carcinoma (HCC)
    Sterling, Richard
    Wise, Margaret
    Kanke, Futoshi
    Jeffers, Lennox
    Gordon, Fredric
    Sherman, Morris
    Venook, Alan
    Reddy, Rajender
    Satomura, Shinji
    Schwartz, Myron
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S161 - S162
  • [30] Diagnostic Performance of Des-γ-carboxy Prothrombin for Hepatocellular Carcinoma: A Meta-Analysis
    Zhu, Rong
    Yang, Jing
    Xu, Ling
    Dai, Weiqi
    Wang, Fan
    Shen, Miao
    Zhang, Yan
    Zhang, Huawei
    Chen, Kan
    Cheng, Ping
    Wang, Chengfen
    Zheng, Yuanyuan
    Li, Jingjing
    Lu, Jie
    Zhou, Yingqun
    Wu, Dong
    Guo, Chuanyong
    GASTROENTEROLOGY RESEARCH AND PRACTICE, 2014, 2014